Targeted Oncology is a pragmatic tool for all physicians and scientists committed to oncology and cancer research.
Recently, a better understanding of the genetics and biology of cancer have provided important clues to the pathology of the disease and to new therapeutic strategies. Innovative treatments, including small molecule inhibitors and biologicals targeting oncogenic pathways and immune checkpoints have emerged and are currently revolutionizing the way we treat cancer patients. Despite these breakthroughs, significant work remains in understanding these new compounds and identifying markers of treatment success.
Targeted Oncology focuses on Original Research Articles on both pre-clinical and clinical aspects of molecularly targeted agents, and on comprehensive narrative Review Articles discussing clinically established as well as emerging agents and pathways. The journal also publishes Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement, and Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.
Targeted Oncology offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.
All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.
There are no publication charges for standard publishing in Targeted Oncology; the journal offers the option of Open Access publication via Springer Open Choice (article processing charge €3,060 / US$3,860). Please click on the link below under ‘Publishing model’ for further information about this service.
- Martin Chopra
- Publishing model
- Hybrid. Open Access options available
- 3.683 (2018)
- Impact factor
- 3.118 (2018)
- Five year impact factor
- 14 days
- Submission to first decision
- 102 days
- Submission to acceptance
- 87,689 (2019)
MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside
Authors (first, second and last of 7)
Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors
Authors (first, second and last of 11)
About this journal
- Electronic ISSN
- Print ISSN
- Abstracted and indexed in
- EBSCO Biomedical Reference Collection
- EBSCO CINAHL
- EBSCO Discovery Service
- Gale Academic OneFile
- Gale InfoTrac
- Google Scholar
- INIS Atomindex
- Institute of Scientific and Technical Information of China
- Japanese Science and Technology Agency (JST)
- Journal Citation Reports/Science Edition
- OCLC WorldCat Discovery Service
- ProQuest Central
- ProQuest Consumer Health
- ProQuest Health & Medical Collection
- ProQuest Health Research Premium Collection
- ProQuest Medical Database
- ProQuest Nursing & Allied Health Database
- ProQuest Pharma Collection
- ProQuest-ExLibris Primo
- ProQuest-ExLibris Summon
- Science Citation Index Expanded (SciSearch)
- Semantic Scholar